Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties. As a technology-driven company dedicated to improving the quality of life of patients throughout the world we identify and address unmet needs in human healthcare, a strategy that is well-integrated into our research and development approach.
The symphonX™ Surgical Platform is our first commercial platform for minimally invasive surgery, and is FDA cleared for use in abdominal laparoscopic surgery. Beyond the initial focus on general surgery, the recently launched shorter version of the symphonX™ Instruments portfolio has been used during several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform across surgical specialties.
Under the leadership and guidance of Dr. Karl-Hermann Fuchs and Dr. Patricia Sylla, both serving on our Scientific Advisory Board , we are developing a surgical solution for less invasive Transanal Colon Resection (TaCR) with the aim of eliminating any access related transabdominal morbidity to improve recovery and lower readmission rates.
Together with his son, Dr. Hans F. Fuchs, several cadaver and dry lab studies were performed with a modified version of the symphonX™ Surgical Platform. These results were presented as part of the Emerging Technology Session of the SAGES 2016 Annual Meeting in Boston (March 2016) and the Amazing Technology Session of the 25th International Congress of the European Association for Endoscopic Surgery (EAES) in Frankfurt am Main (June 2017) by Dr. Hans F. Fuchs, and during the American Society For Gastrointestinal Endoscopy (ASGE) NOSCAR Summit in Downers Grove (July 2017) by Dr. Karl-Hermann Fuchs.
With a team of innovative surgeons, including Dr. Joseph A. Califano and Dr. Philip Weissbrod, we are developing a minimally invasive surgical platform to improve overall procedural efficiency and precision of dissection in transoral surgery within the oropharynx and larynx.
During a cadaveric lab in December 2018, a wide range of procedures within the oropharynx, larynx, and hypopharynx was found to be feasible using the Fortimedix transoral surgery platform.
Excellent accuracy (no tremor) and ease-of-use enabled delicate micro-flap elevation of the true vocal fold. The strength, range of motion and dexterity of the prototype instruments also facilitated partial laryngeal, subglottic mucosa and tongue base resection, as well as cricopharyngeal myotomy. Dr. Emily K. Funk will be presenting the results of this initial study during the Emerging Technology Session of the SAGES 2019 Annual Meeting in Baltimore, MD (April 3-6, 2019).
“We’re heading towards doing surgery in flexible endoscopy”
EAES Congress, Frankfurt (14 – 17 June, 2017)
Scientific Session: Old & New Robots
Endoscopic Submucosal Dissection (ESD) and Endoscopic Full Thickness Resection (EFTR) are advanced endoscopic techniques which can be time consuming using traditional endoscopic instruments. Under the visionary leadership of our Scientific Advisory Board members, we are creating a novel endo-surgery platform for flexible endoscopic therapy in the gastrointestinal (GI) tract, bringing laparoscopic technique to traditional flexible endoscopes. Our objective is to treat GI diseases directly and less invasively and avoid any collateral damage from major dissection to reach the diseased area, to improve clinical outcome and procedural efficiency.
During an upper GI porcine study at the Center for the Future of Surgery (UC San Diego) in December 2018, the functional capabilities of the platform and flexible articulating handheld instruments were evaluated. The distal esophagus and stomach could easily be accessed and the platform was effectively deployed. ESD was successfully performed, using our novel endo-surgery platform applied to a standard flexible endoscope, with good triangulation, excellent traction and re-traction, and sufficient grasping forces. Future studies are planned to determine the learning curve and compare it to traditional endoscopic instruments.
Therapeutic endoscopy such as endoscopic tumor resections in the GI tract may be facilitated by more advanced instruments for suturing. In close collaboration with a team of exceptional surgeons at UC San Diego, we are developing a new EndoSuture instrument system for flexible endoscopic suturing in the GI tract. Our aim is to close leaks and bleeds in the upper GI tract and distal colon to improve healing and accelerate recovery. The first porcine model test series in the distal esophagus showed that our novel EndoSuture flexible articulating instruments, used in combination with a standard flexible endoscope, are feasible to perform dependable intraluminal suturing. The training period and learning curve is short. The objective is to apply this system clinically in the near future for closure of perforations and fistulas. Dr. K-H Fuchs will be presenting the EndoSuture body of research at the 27th European Association for Endoscopic Surgery (EAES) Meeting in Sevilla, Spain (June 12-15, 2019).
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words.
All forward looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally.
Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.